Assignee
JOINT STOCK COMPANY «BIOCAD»
RU·16 granted patents·5 pending applications·12 citations·filing 2016–2023
Top patents by PatentIndex Score
21 records- 0183US12227572B2Monoclonal antibodies against the beta chain region of human TRBV9JOINT STOCK COMPANY “BIOCAD”·Filed 2020·Granted Feb 18, 2025·2 cites·16 claims
- 0277US12297269B2Monoclonal antibodies that bind specifically to human TRBV9JOINT STOCK COMPANY “BIOCAD”·Filed 2019·Granted May 13, 2025·2 cites·22 claims
- 0376US11136408B2Anti-PD-1 antibodies, method for producing same and method for using sameJOINT STOCK COMPANY “BIOCAD”·Filed 2017·Granted Oct 5, 2021·3 cites·16 claims
- 0472US11840567B2Bispecific antibodies with specific binding to CD47 and PD-L1JOINT STOCK COMPANY “BIOCAD”·Filed 2018·Granted Dec 12, 2023·1 cites·13 claims
- 0570US11597767B2Monoclonal antibodies that bind TRBV9 and methods for using same for inhibiting the T cell receptor for treatmentJOINT STOCK COMPANY “BIOCAD”·Filed 2018·Granted Mar 7, 2023·2 cites·13 claims
- 0670US11236167B2Monoclonal antibody to PD-L1JOINT STOCK COMPANY “BIOCAD”·Filed 2018·Granted Feb 1, 2022·2 cites·21 claims
- 0764US12514923B2Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9JOINT STOCK COMPANY “BIOCAD”·Filed 2023·Granted Jan 6, 2026·0 cites·17 claims
- 0858US2025340613A1Bispecific antibody comprising a heterodimer based on mhc proteinsJOINT STOCK COMPANY «BIOCAD»·Filed 2022·Application pending·0 cites
- 0954US2025333749A1Inducible promoter, vector and host cell based thereonJOINT STOCK COMPANY «BIOCAD»·Filed 2022·Application pending·0 cites
- 1050US12202906B2Monoclonal antibody that specifically binds to CD20JOINT STOCK COMPANY “BIOCAD”·Filed 2019·Granted Jan 21, 2025·0 cites·14 claims
- 1149US2025346667A1Pharmaceutical composition of anti-trbv9 antibody and use thereofJOINT STOCK COMPANY «BIOCAD»·Filed 2023·Application pending·0 cites
- 1248US2024076691A1Codon-optimized nucleic acid encoding the fix proteinJOINT STOCK COMPANY «BIOCAD»·Filed 2022·Application pending·0 cites
- 1346US11447574B2Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17AJOINT STOCK COMPANY “BIOCAD”·Filed 2019·Granted Sep 20, 2022·0 cites·18 claims
- 1445US2024091383A1Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophyJOINT STOCK COMPANY «BIOCAD»·Filed 2022·Application pending·0 cites
- 1543US12534525B2Aqueous pharmaceutical composition of an anti-IL17A antibody and use thereofJOINT STOCK COMPANY “BIOCAD”·Filed 2020·Granted Jan 27, 2026·0 cites·23 claims
- 1643US12173075B2Anti-IL-5RAlpha monoclonal antibodyJOINT STOCK COMPANY “BIOCAD”·Filed 2018·Granted Dec 24, 2024·0 cites·26 claims
- 1743US12173336B2PaCas9 nucleaseJOINT STOCK COMPANY “BIOCAD”·Filed 2019·Granted Dec 24, 2024·0 cites·8 claims
- 1839US12410257B2Monoclonal antibody that binds specifically to GITRJOINT STOCK COMPANY “BIOCAD”·Filed 2020·Granted Sep 9, 2025·0 cites·26 claims
- 1938US11993647B2Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6JOINT STOCK COMPANY “BIOCAD”·Filed 2017·Granted May 28, 2024·0 cites·11 claims
- 2029US11840531B2CDK8/19 inhibitorsJOINT STOCK COMPANY “BIOCAD”·Filed 2019·Granted Dec 12, 2023·0 cites·15 claims
- 2128US11453717B2Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory moleculeJOINT STOCK COMPANY “BIOCAD”·Filed 2016·Granted Sep 27, 2022·0 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when JOINT STOCK COMPANY «BIOCAD» files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →